Answers are grounded in this paper and cite their sources.
Among the mechanisms responsible for cognitive dysfunction in chronic kidney disease (CKD) are albuminuria and oxidative stress. However, there may be other causes not yet identified. In fact, the full relevance of CKD patient drug use and its relationship to dementia has hardly been barely investigated. We identified drugs affecting cognitive function in CKD patients by analyzing the spontaneous reporting system in Japan using Association rule mining (ARM) and Bayesian confidence propagation neural network (BCPNN). The signal detection criterion used were as follows: case ≥ 3, lift > 1, conviction > 1 (ARM) and IC 025 >0 (BCPNN). Drugs with more than 20 cases were valaciclovir (lift: 11.21, conviction: 1.28, IC 025: 3.12), amantadine (lift: 19.69, conviction: 1.68, IC 025: 3.05), nalfurafine (lift: 8.35, conviction: 1.19, IC 025: 2.18), pregabalin (lift: 6.05, conviction: 1.12, IC 025: 1.78), and acyclovir (lift: 5.89, conviction: 1.12, IC 025: 1.68). This study is the first report to use a large-scale medical database to identify drugs related to oral drugs-induced dementia in CKD.
No takes yet. Share an insight, caveat, or question.
Noguchi et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: